Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit [Yahoo! Finance]
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Century Therapeutics, Inc. (NASDAQ: IPSC) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $9.00 price target on the stock, down previously from $10.00.
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics [Yahoo! Finance]
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics